News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Incyte
NEWS
JOBS
IN THE PRESS
NEWS
Policy
Blood Clot Fears Delay Eli Lilly, Incyte’s Potential Rheumatoid Arthritis Blockbuster, Stocks Fall
July 25, 2017
·
3 min read
Deals
Why Incyte Is Still A Good Backup Plan For Gilead
July 14, 2017
·
1 min read
Business
Gilead’s Rumored M&A Target Incyte Doubled CEO’s Pay Package in 2016
April 18, 2017
·
1 min read
FDA
FDA Just Rejected Eli Lilly, Incyte’s Rheumatoid Arthritis Drug Baricitinib
April 14, 2017
·
2 min read
Deals
Why These 3 Drugmakers Could Buy Incyte
April 12, 2017
·
3 min read
Deals
What Happens if Gilead Went Bigger Than Incyte and Made a Play for This Pharma Giant
April 10, 2017
·
2 min read
BioCapital
After Soaring to $150, Can Incyte Stir Up More Upside?
March 16, 2017
·
1 min read
Deals
3 Reasons Why Gilead Will Buy Incyte—and 1 Reason Why It Won’t
March 15, 2017
·
1 min read
Deals
What a Gilead-Incyte Marriage Would Look Like
March 14, 2017
·
2 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
January 28, 2026
·
1 min read
Press Releases
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
January 5, 2026
·
9 min read
Press Releases
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
December 23, 2025
·
7 min read
Press Releases
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
December 23, 2025
·
7 min read
Press Releases
Incyte to Present at Upcoming Investor Conference - December 18, 2025
December 19, 2025
·
1 min read
Press Releases
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
December 18, 2025
·
9 min read
Press Releases
Incyte Announces Change to its Board of Directors
December 15, 2025
·
1 min read
Press Releases
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
December 9, 2025
·
10 min read
Press Releases
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
December 8, 2025
·
17 min read
Press Releases
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
December 8, 2025
·
6 min read
